<DOC>
	<DOC>NCT01186432</DOC>
	<brief_summary>This study will evaluate the preliminary safety and efficacy of PDS 1.0 in patients with neovascular AMD.</brief_summary>
	<brief_title>Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated Retinal thickness due to edema of at least 300um in the study eye Best corrected visual acuity of 20/40 or worse in the study eye Best corrected visual acuity of 20/40 or better in the fellow eye Evidence of scarring CNV (e.g. geographic atrophy) in the study eye Fibrosis &gt;75% of lesion area in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>